PLRX实时信号 | 通过Getagraph.com最大化利润

购买 107736 min ago

@ $16.43

发出时间: 15 Feb 2024 @ 04:44

回报率: -24.51%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: 5.47 %

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 00:18):

Stats
今日成交量	93 748.00
平均成交量	371 556
市值	747.95M
EPS	$-0.690 ( 2024-03-28 )
下一个收益日期	( $-0.770 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.51
ATR14	$0.0230 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-23	Lefebvre Eric	Buy	42 900	Common Stock
2024-01-23	Lefebvre Eric	Buy	85 800	Stock Option (Right to Buy)
2024-01-23	Hull Hans	Buy	31 500	Common Stock
2024-01-23	Hull Hans	Buy	63 000	Stock Option (Right to Buy)
2024-01-23	Ouimette Mike	Buy	31 500	Common Stock

INSIDER POWER
67.14
Last 98 transactions
Buy: 2 502 892 \| Sell: 552 083

音量相关性

長: -0.23 (neutral)

短: -0.79 (moderate negative)

Signal:(66.766) Neutral

Pliant Therapeutics Inc 相关性

10 最正相关
PAIC	0.955
CSII	0.935
ADMS	0.932
RESN	0.927
HSKA	0.921
ZGNX	0.918
OLMA	0.915
NATI	0.914
IPW	0.912
SVAC	0.911

10 最负相关
NETE	-0.945
BOCH	-0.932
MMAC	-0.914
RAVN	-0.912
SHSP	-0.879
SBBP	-0.876
CFV	-0.873
AMRB	-0.869
ORMP	-0.869
AZTA	-0.861

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Pliant Therapeutics Inc 相关性 - 货币/商品

0.84
( strong )

0.86
( strong )

0.00
( neutral )

0.80
( moderate )

0.72
( moderate )

-0.84
( strong negative )

Pliant Therapeutics Inc 财务报表

Annual	2023
营收:	$1.58M
毛利润:	$-261 000 (-16.52 %)
EPS:	$-2.75

FY	2023
营收:	$1.58M
毛利润:	$-261 000 (-16.52 %)
EPS:	$-2.75

FY	2022
营收:	$9.69M
毛利润:	$6.00M (61.99 %)
EPS:	$-2.89

FY	2021
营收:	$7.57M
毛利润:	$0.00 (0.00 %)
EPS:	$-2.71

Financial Reports:

No articles found.

Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.